VECTUS BIOSYSTEMS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.08 AUD | 0.00% |
|
-13.04% | -73.33% |
| 05-23 | Vectus Biosystems Appoints CTO | MT |
| 05-20 | Vectus Biosystems CEO Passes Away | MT |
| Sales 2022 | 1.3M 867K 1.18M | Sales 2023 | 1.35M 903K 1.23M | Capitalization | 23.4M 15.6M 21.3M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -2M -2.73M | Net income 2023 | -3M -2M -2.73M | EV / Sales 2022 | 31 x |
| Net Debt 2022 | 4.73M 3.16M 4.31M | Net cash position 2023 | 2.88M 1.92M 2.62M | EV / Sales 2023 | 15.2 x |
| P/E ratio 2022 |
-8.23
x | P/E ratio 2023 |
-6.12
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.2% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -13.04% | ||
| Current month | -38.46% | ||
| 1 month | -38.46% | ||
| 3 months | -68.63% | ||
| 6 months | -74.19% | ||
| Current year | -73.33% |
1 week
0.08
0.09
1 month
0.080.13
Current year
0.080.32
1 year
0.080.50
3 years
0.082.20
5 years
0.082.20
10 years
0.082.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Corporate Secretary | - | 15-07-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Maurie Stang
BRD | Director/Board Member | - | 05-12-11 |
Ronald Shnier
CHM | Chairman | - | 15-09-01 |
Susan Pond
BRD | Director/Board Member | - | 16-05-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-24 | 0.08 | 0.00% | 23,090 |
| 24-06-21 | 0.08 | -5.88% | 61,189 |
| 24-06-20 | 0.085 | -2.30% | 55,486 |
| 24-06-19 | 0.087 | -5.43% | 54,486 |
| 24-06-18 | 0.092 | -4.17% | 22,490 |
Delayed Quote Australian S.E., June 24, 2024 at 12:57 am
More quotes
Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -73.33% | 2.84M | |
| +38.36% | 52.5B | |
| +36.73% | 39.31B | |
| -8.63% | 39.01B | |
| +25.46% | 28.2B | |
| -11.17% | 26.57B | |
| +11.44% | 26.2B | |
| +45.09% | 14.15B | |
| +32.93% | 12.62B | |
| -5.30% | 11.74B |
- Stock Market
- Equities
- VBS Stock
